ITT indicates intention to treat; QLQ, Quality of Life Questionnaire–Core30.
A, Objective response rate (ORR) measured with Response Evaluation Criteria in Solid Tumors, version 1.1, was 57.4% (95% CI, 47.8%-66.6%) in the standard arm and 56.5% (95% CI, 47.0%-65.7%) in the experimental arm. Odds ratio of response of experimental vs standard treatment was 0.96 (95% CI, 0.55-1.68; P = .89). B, Data are shown in the intention-to-treat population at the first data cutoff (December 31, 2019). Progression-free survival was 10.5 (95% CI, 9.1-12.3) months in the standard arm vs 11.7 (95% CI, 9.9-12.9) months in the experimental arm. The adjusted hazard ratio (HR) for the experimental arm vs the standard arm was 0.81 (95% CI, 0.62-1.08; P = .15). C, Overall survival at the median follow-up of 68.3 [interquartile range, 57.5-70.9] months was 24.1 (95% CI, 18.6-29.8) months in the standard arm vs 29.8 (95% CI, 22.5-41.1) months in the experimental arm (HR, 0.73; 95% CI, 0.54-0.99; P = .04).
eFigure 1. Scatterplot of the Timing of the Evaluation of Objective Response by Study Arm During Chemotherapy Treatment (12 and 24 Weeks After Randomization)
eFigure 2. Forest Plot of Progression-Free Survival by Patient Subgroups
eFigure 3. Forest Plot of Overall Survival by Patient Subgroups
eFigure 4. Analysis of Diarrhea Occurrence
eFigure 5. Analysis of Nausea Occurrence
eFigure 6. Analysis of Fatigue Occurrence
eFigure 7. Mean Changes From Baseline by Study Arm in EORTC QLQ-C30 Functional Scales
eFigure 8. Mean Changes From Baseline by Study Arm in EORTCQLQ-C30 Symptom Items
eTable 1. Compliance With Planned Treatment
eTable 2. Best Overall Response to Treatment by Subgroups RAS Status
eTable 3. Metastases-Resected Patients
eTable 4. Postprogression Therapies According to Treatment Arm
eTable 5. Worst per Patient Adverse Events Reported During Treatment, Classified According to the CTCAE, Version 4.0
eTable 6. Distribution of Best QOL Response From Baseline With EORTC QLQ-C30 Global Health Status, Functional Scales, and Symptom Items
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Avallone A, Piccirillo MC, Nasti G, et al. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(7):e2118475. doi:10.1001/jamanetworkopen.2021.18475
Does sequential scheduling of bevacizumab administration in combination with chemotherapy improve treatment efficacy in patients with metastatic colorectal cancer in keeping with the tumor vascular normalization hypothesis?
In this phase 3 randomized clinical trial of 230 patients, the primary end point objective response rate did not significantly differ between the sequential and the concomitant schedule of bevacizumab administration in combination with standard oxaliplatin-based regimens. However, the sequential schedule of bevacizumab administration was associated with longer overall survival, fewer adverse effects, and better health-related quality of life.
Sequential bevacizumab scheduling plus chemotherapy might be relevant to optimize therapeutic efficacy and to explore antiangiogenic combination treatments with innovative perspectives.
Although bevacizumab is a standard of care in combination treatments for metastatic colorectal cancer (mCRC), its clinical benefit has been limited.
To determine whether sequential scheduling of bevacizumab administration in combination with chemotherapy improves treatment efficacy in patients with mCRC, in keeping with the tumor vascular normalization hypothesis.
Design, Setting, and Participants
This open-label, randomized clinical phase 3 trial was conducted from May 8, 2012, to December 9, 2015, at 3 Italian centers. Patients aged 18 to 75 years with unresectable, previously untreated, or single line–treated mCRC were recruited. Follow-up was completed December 31, 2019, and data were analyzed from February 26 to July 24, 2020.
Patients received 12 biweekly cycles of standard oxaliplatin-based regimens (modified FOLFOX-6 [levo–folinic acid, fluorouracil, and oxaliplatin]/modified CAPOX [capecitabine and oxaliplatin]) plus bevacizumab administered either on the same day as chemotherapy (standard arm) or 4 days before chemotherapy (experimental arm).
Main Outcomes and Measures
The primary end point was the objective response rate (ORR) measured with Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival, overall survival, safety, and quality of life (QOL).
Overall, 230 patients (136 men [59.1%]; median age, 62.3 [interquartile range, 53.3-67.6] years) were randomly assigned to the standard arm (n = 115) or the experimental arm (n = 115). The median duration of follow-up was 68.3 (95% CI, 61.0-70.0) months. No difference in ORR (57.4% [95% CI, 47.8%-66.6%] in the standard arm and 56.5% [95% CI, 47.0-65.7] in the experimental arm; P = .89) or progression-free survival (10.5 [95% CI, 9.1-12.3] months in the standard arm and 11.7 [95% CI, 9.9-12.9] months in the experimental arm; P = .15) was observed. However, the median overall survival was 29.8 (95% CI, 22.5-41.1) months in the experimental arm compared with 24.1 (95% CI, 18.6-29.8) months in the standard arm (adjusted hazard ratio, 0.73; 95% CI, 0.54-0.99; P = .04). Moreover, the experimental arm was associated with a significant reduction in the rate of severe diarrhea (6 [5.3%] vs 19 [16.5%]; P = .006) and nausea (2 [1.8%] vs 8 [7.0%]; P = .05) and improved physical functioning (mean [SD] change from baseline, 0.65 [1.96] vs −7.41 [2.95] at 24 weeks; P = .02), and constipation scores (mean [SD] change from baseline, −17.2 [3.73] vs −0.62 [4.44]; P = .003).
Conclusions and Relevance
In this randomized clinical trial, sequential administration of bevacizumab plus chemotherapy did not improve ORR, the primary end point. However, the overall survival advantage, fewer adverse effects, and better health-related QOL associated with sequential bevacizumab administration might provide the basis for exploring antiangiogenic combination treatments with innovative perspectives.
EudraCT Identifier: 2011-004997-27; ClinicalTrials.gov Identifier: NCT01718873
The treatment of metastatic colorectal cancer (mCRC) has improved significantly with the addition of new cytotoxic drugs and biological agents to fluoropyrimidine regimens.1 However, mCRC remains incurable in most cases, and no novel drugs have been included in the therapeutic arsenal against this disease in recent years. In this scenario, optimization of the combined use of available drugs with proven efficacy provides a relevant challenge.
Angiogenesis has emerged as a crucial hallmark of cancer development, becoming a key target for cancer treatment of various solid tumors, including CRC.2,3 Tumor angiogenesis is highly dependent on the activity of vascular endothelial growth factor (VEGF) and is characterized by structural and functional vasculature abnormalities leading to a hostile microenvironment that impedes drug delivery and fuels tumor invasion and treatment resistance.4-6 Bevacizumab, a humanized monoclonal antibody directed against VEGF, is the standard of care for the treatment of mCRC in the first- and second-line setting in combination with conventional chemotherapy.7
The clinical benefit of bevacizumab combination treatments, however, has proven to be rather limited and occasionally questioned in mCRC.8-10 Moreover, the disappointing clinical results of bevacizumab monotherapy indicate that its mechanism of action is not confined to tumor starvation as originally postulated.11-13 Indeed, the mechanism by which bevacizumab improves the efficacy of chemotherapy remains under active investigation.14
Several preclinical and clinical studies suggest that an important therapeutic mechanism of anti-VEGF agents is the induction of tumor vascular normalization.15 Tumor vascular normalization occurs 4 to 5 days after bevacizumab treatment. Sequential scheduling aimed at normalizing vasculature before delivery of chemotherapeutics could be of considerable importance to optimize the efficacy of combination treatment.5,16,17
Avallone et al18 demonstrated the critical role of bevacizumab scheduling in patients with locally advanced rectal cancer (BRANCH [Bevacizumab, Radiotherapy and Chemotherapy] trial). Bevacizumab administered 4 days before presurgical chemoradiotherapy resulted in a higher rate of complete tumor regression and a better toxicity profile compared with the traditional concomitant schedule. Following up on these findings, an academic multicenter randomized phase 3 study was designed to compare concomitant and sequential scheduling of bevacizumab in combination with standard oxaliplatin-based regimens in untreated or single line–treated patients with mCRC.19
The OBELICS (Optimization of Bevacizumab Scheduling Within Chemotherapy) study was an open-label, 2-arm, randomized clinical phase 3 trial conducted in 3 Italian centers. The trial was approved by the ethics committees of the participant sites, and all patients provided written informed consent. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.
Randomization was performed by a centrally computer-generated minimization procedure accounting for center, Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1), previous chemotherapy for advanced disease (yes vs no), and number of metastatic sites (1 vs >1) to balance the distribution of these factors between the 2 treatment arms. Patients aged 18 to 75 years with histologically confirmed unresectable mCRC regardless of RAS (OMIM 190070 and 164790) mutational status, with no more than 1 previous treatment line, and with an ECOG performance status of 1 or less were eligible. Adequate hematologic, hepatic, and renal function and adequate recovery from recent surgery (at least 28 days after a major surgery or biopsy) were required. The study protocol (Supplement 1) has been reported previously.19 Mutational status of tumor RAS, KRAS (OMIM 190070) and NRAS (OMIM 164790) exons 2 to 4, as well as BRAF codon 600 (OMIM 164757), were assessed on DNA extracted from archival tissue specimens from the primary tumor or metastases as reported elsewhere.20
Patients were randomized (1:1) to receive 12 biweekly cycles of a modified FOLFOX-6 regimen (intravenous oxaliplatin, 85 mg/m2, on day 1, followed by intravenous levo–folinic acid, 200 mg/m2, plus bolus fluorouracil, 400 mg/m2, and a 46-hour intravenous administration of fluorouracil, 2400 mg/m2) or a modified CAPOX regimen (intravenous oxaliplatin, 85 mg/m2, on day 1 plus oral capecitabine, 1000 mg/m2, twice daily on days 1 to 10) every 2 weeks21 for 12 cycles. Bevacizumab (5 mg/kg) was administered on the same day as chemotherapy (standard arm) or 4 days before (experimental arm).
Maintenance treatment with bevacizumab with or without fluoropyrimidines was planned in both arms until progression or unacceptable toxic effects. In case of prespecified adverse events, treatment modifications were allowed as outlined in the study protocol (Supplement 1).19 Surgery could be performed if a patient became eligible for curative resection of metastatic disease; the choice of treatment after surgery was at the discretion of the investigator.
Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was the primary end point and was defined as the number of complete plus partial responses divided by the number of enrolled patients. Objective response was assessed by computed tomographic scan or other appropriate imaging at weeks 12 and 24 from randomization and every 3 months thereafter. Disease control rate was calculated by adding complete and partial responses and stable disease. Secondary end points included progression-free survival (PFS), overall survival (OS), toxic effects, and quality of life (QOL). Progression-free survival was defined as the time from randomization to the date of progression or death, whichever occurred first. Patients without progression were censored on the date of the last follow-up visit. Overall survival was defined as the time from randomization to the date of death. Patients alive at the time of the final analysis were censored on the date of the last follow-up information available. Toxic effect were scored according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. Quality of life was assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core30, version 3.0, questionnaire at baseline and at week 12 and 24 during treatment, in both arms.
Biomarker studies on tumor and blood samples (Supplement 1) and [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography evaluation were also planned, as reported previously.19 The results of correlative studies will be described separately.
Data were analyzed from February 26 to July 24, 2020. Study sample size was calculated considering different possible proportions of patients enrolled for first- or second-line treatment. Assuming an ORR of 40% in the first line and 20% in the second line, an anticipated odds ratio of 2.25, 80% power, and 5% 2-sided α error, and considering that the needed sample size increases with the lowering of the ORR expected in the standard arm, a sample size of 230 patients was determined to be adequate to verify the study hypothesis also in the extreme case of 75% of patients enrolled for second-line chemotherapy (that corresponds to an expected ORR of 25% with standard treatment).
All analyses were performed based on an intention-to-treat strategy. The ORRs in the 2 arms were reported with 95% CIs and were compared with the χ2 test in a 2 × 2 contingency table (responders and nonresponders × treatment arms). The median duration of disease control was estimated using time-to-event analysis with a Cox proportional hazards regression model, with an event considered as progression after a complete or partial response or stable disease. Median follow-up was calculated according to the reverse Kaplan-Meier technique of Schemper.45 Survival curves were described according to the Kaplan-Meier product-limit method. Estimated hazard ratios (HRs) and their 95% CIs were calculated using the Cox proportional hazard model adjusted by ECOG performance status, previous chemotherapy for advanced disease, number of metastatic sites, and RAS mutational status as covariates and stratified by type of chemotherapy regimen chosen by the investigator. First-order interactions between treatment and main prognostic variables were tested by the likelihood ratio test of 2 nested models with and without interaction. Patients who received at least 1 study drug dose were eligible for safety analysis. For each patient and type of toxic effects, the worst degree observed during treatment was used for analysis. Differences between study arms in the whole pattern of toxic effects (all grades) for each item were analyzed with a linear permutation test accounting for ordinal nature of data (linear rank test). Occurrence of any grade (>0) and severe (>2) toxic effects were also compared between the 2 arms with the χ2 test. Mean changes from baseline in global health status and QOL items at each point were compared between the 2 arms in a linear regression model, adjusted by the previous covariates and the baseline QOL scores.22 The best QOL response from baseline for each domain or symptom was calculated by defining a score change of at least 10 points from baseline as clinically relevant and comparing the 2 arms with the χ2 test.23 No adjustment was applied for multiple comparisons, owing to the explorative nature of secondary and subgroup analyses. Follow-up was completed on December 31, 2019. Statistical analyses were performed using STATA MP, version 14.1 (StataCorp LLC); 2-sided P < .05 indicated statistical significance.
From May 8, 2012, to December 9, 2015, 230 patients (136 men [59.1%] and 94 women [40.9%]; median age, 62.3 [interquartile range (IQR), 53.3-67.6] years) were randomized to the standard arm (n = 115) or to the experimental arm (n = 115). Information on treatment was missing for 1 patient in the experimental arm who was not included in the safety analysis (Figure 1). Baseline patient characteristics were well balanced between the treatment arms (Table 1), but a higher proportion of patients with RAS mutations were included in the experimental arm (71 [61.7%] vs 54 [47.0%]; P = .06).
Most of the patients (167 [72.6%]) received the modified FOLFOX-6 regimen. The median number of cycles was 12 (IQR, 10-12) in both arms. More patients in the standard arm required treatment delay (30 [26.1%] vs 22 [19.3%]) and dose reduction (14 [12.2%] vs 6 [5.3%]), whereas more patients completed treatment induction in the experimental arm (83 [72.8%] vs 78 [67.8%]) (eTable 1 in Supplement 2). Forty-four patients in the standard arm (38.3%) and 52 patients in the experimental arm (45.2%) received maintenance therapy, with a median number of cycles administered per patient of 4 (IQR, 2-6) and 6 (IQR, 4-8), respectively, and with most of these patients receiving bevacizumab plus fluoropyrimidines in both arms (38 of 44 [86.4%] and 46 of 52 [88.5%], respectively) (eTable 1 in Supplement 2).
No difference in ORR was observed between the 2 arms with an odds ratio of response for experimental vs standard treatment equal to 0.96 (95% CI, 0.55-1.68; P = .89) (Figure 2A). Complete or partial responses were reported in 66 patients in the standard arm (57.4%; 95% CI, 47.8%-66.6%) and 65 patients in the experimental arm (56.5%; 95% CI, 47.0%-65.7%) (Table 2). The disease control rate (103 [89.6%] for the standard arm vs 107 [93.0%] for the experimental arm) (Table 2) and median duration of disease control (6.6 [IQR, 5.3-8.6] months for the standard arm vs 7.1 [IQR, 5.7-9.0] months for the experimental arm) were also similar. Overall, a better ORR was observed in the RAS wild-type subgroups (35 of 54 [64.8%] for the standard arm and 26 of 37 [70.3%] for the experimental arm), with no difference between the 2 arms according to RAS status (29 of 54 [53.7%] vs 37 of 71 [52.1%] for RAS variant subgroups and 1 of 7 [14.3%] vs 2 of 7 [28.6%] for RAS unknown subgroups in the standard and experimental arms, respectively) (eTable 2 in Supplement 2). The number of BRAF-altered tumors was too small to allow correlation with outcomes. The timing of the evaluation of the objective response was similar between the 2 arms (eFigure 1 in Supplement 2).
No significant differences in the proportion of patients who underwent resection of metastases and in radical resection rate were observed between the 2 arms (eTable 3 in Supplement 2). At the end of follow-up (December 31, 2019), with a median follow-up of 68.3 (95% CI, 61.0-70.0) months, 211 PFS events occurred, 107 in the standard arm and 104 in the experimental arm. The median PFS was 10.5 (95% CI, 9.1-12.3) and 11.7 (95% CI, 9.9-12.9) months for the standard and experimental arms, respectively, with an adjusted HR of 0.81 (95% CI, 0.62-1.08; P = .15) (Figure 2B). The treatment effect on PFS was consistent across all clinical and molecular subgroups (eFigure 2 in Supplement 2). Overall, 182 patients died, 95 in the standard arm and 87 in the experimental arm. The median OS was 24.1 (95% CI, 18.6-29.8) and 29.8 (95% CI, 22.5-41.1) months for the standard and experimental arms, respectively, with an adjusted HR of 0.73 (95% CI, 0.54-0.99; P = .04) (Figure 2C). Overall survival benefit in the experimental arm was homogeneous in all clinical and molecular subgroups (eFigure 3 in Supplement 2).
The number of patients undergoing subsequent systemic therapies was similar in both arms (eTable 4 in Supplement 2). Among patients receiving second-line treatment, a significantly higher proportion of patients received a regimen containing anti–epidermal growth factor receptor (EGFR) in the standard arm (31 [27.0%] vs 21 [18.3%]) and a significantly higher proportion received an anti-VEGF–containing regimen in the experimental arm (49 [42.6%] vs 31 [27.0%]) as a consequence of the imbalance of patients in the RAS wild-type subgroups in the 2 arms. No significant difference in the distribution of subsequent treatment lines was observed between the 2 arms.
No unexpected toxic effects were reported. Adverse events occurring in at least 3% of patients are reported in Table 3 (complete information is provided in eTable 5 in Supplement 2). Patients receiving standard treatment experienced significantly more fatigue (30 [26.1%] vs 16 [14.0%]; P = .02), abdominal pain (10 [8.7%] vs 3 [2.6%]; P = .047), and diarrhea (44 [38.3%] vs 27 [23.7%]; P = .01), which was also more frequently severe (19 [16.5%] vs 6 [5.3%]; P = .006), as was nausea (8 [7.0%] vs 2 [1.8%]; P = .052). Moreover, the probability of developing diarrhea of any grade per cycle was significantly higher with standard treatment (12-month cumulative probability, 0.41 [95% CI, 0.32-0.51] vs 0.25 [95% CI, 0.18-0.35]) (eFigures 4-6 in Supplement 2). Significantly more proteinuria was reported in the experimental arm (10 [8.8%] vs 3 [2.6%]; P = .049). Moreover, although lower platelet levels (32 [27.8%] vs 20 [17.5%]; P = .08) as well as more epistaxis (7 [6.1%] vs 15 [13.2%]; P = .07) were observed in the experimental arm compared with the standard arm, the difference was not statistically significant. Deaths due to toxic effects included 2 patients (with an ileal perforation and a sudden death) in the standard arm and 2 patients (with a colon perforation and a rectal perforation) in the experimental arm.
The QOL questionnaire at baseline was completed by 203 patients (88.3%; 100 in the standard arm and 103 in the experimental arm). At least 1 later questionnaire was available for 163 patients (70.9%; 77 in the standard and 86 in the experimental arms). The global health status/QOL scores at cycles 6 and 12 were higher in patients in the experimental arm, but the difference was not statistically significant (eFigure 7 in Supplement 2). A significant improvement was shown at cycle 12 in physical functioning score (mean [SD] change from baseline, 0.65 [1.96] vs −7.41 [2.95]; P = .02) (eFigure 7 in Supplement 2) and constipation scores (mean [SD] change from baseline, −17.2 [3.73] vs −0.62 [4.44]; P = .003) (eFigure 8 in Supplement 2). Overall, 33 of 77 (42.9%) and 40 of 86 (46.5%) patients in the standard and experimental arms, respectively, reported an improvement as best QOL response in global health status (P = .41). Significantly more patients reported an improvement as best QOL response in physical functioning (14 of 77 [18.2%] vs 26 of 86 [30.2%]; P = .04) and constipation (19 of 77 [24.7%] vs 34 of 86 [39.5%]; P = .04) in the experimental arm (eTable 6 in Supplement 2).
To our knowledge, this is the first randomized clinical phase 3 trial comparing traditional concurrent and experimental sequential administration of bevacizumab in combination with standard oxaliplatin-based chemotherapy regimens in patients with mCRC. Considering the primary end point, the study failed to show any difference in ORR between treatment arms. Similarly, there was no significant difference in PFS. However, a significant advantage in OS was observed for patients in the sequential arm compared with the concurrent arm. Although OS was a secondary end point and therefore should be considered an exploratory measure of outcome, this result is of interest considering that the 2 treatment arms differed only in the bevacizumab scheduling. Given the long-term median follow-up of more than 60 months, the number of OS events appears adequately mature. The pattern of outcome of the standard arm is in keeping with the results reported in similar populations of patients with mCRC in the RAS unselected subgroup.24-26
The 2 treatment arms were well balanced for primary tumor site and other prognostic factors, except for RAS mutations, which were more represented in the experimental arm. In this regard, although RAS mutant status can influence intratumoral VEGF levels,27 the data on the predictive role of VEGF for bevacizumab-based combination treatment are largely inconsistent and, similar to RAS, a negative prognostic role has been highlighted.27,28
Furthermore, the timing of tumor response assessment was well balanced between the 2 treatment groups, and no difference in the curative rates of resection for metastases was observed. Therefore, it appears unlikely that the statistically significant OS advantage observed in the experimental arm was confounded by study management or influenced by favorable patient selection.
In addition, one of the strengths of this study was the systematic collection of data on second and subsequent therapies after progression, showing a percentage of treated patients in keeping with data reported previously.29 We did not observe any difference between the 2 arms in the number of patients undergoing subsequent systemic therapies; however, a higher percentage of patients in the standard arm received an anti-EGFR–containing regimen in the second line, reflecting the imbalance in distribution of patients with RAS wild-type alterations. Nevertheless, we did not observe any interaction between treatment outcome and RAS variant status, indicating that a putative reduced efficacy of anti-EGFR antibodies after antiangiogenic therapy, as reported by Bennouna et al,30 seems an unlikely explanation of the OS advantage observed in the experimental arm.
With respect to safety, the overall toxicity profile in both treatment arms was in agreement with that reported in previous clinical studies investigating oxaliplatin-based doublet plus bevacizumab regimens,10,31 and no unexpected toxic effects were observed in our study. However, the experimental arm was associated with fewer adverse events, particularly in terms of diarrhea and fatigue. Notably, the better toxicity profile observed in the experimental arm is consistent with previous findings from the phase 2 BRANCH study,18 exploring a similar alternative schedule of bevacizumab administration plus chemotherapy during presurgical radiotherapy in high-risk patients with locally advanced rectal cancer.
As a consequence of the more favorable safety profile, the experimental arm was also associated with better treatment compliance and health-related QOL. Indeed, more patients completed treatment induction and received maintenance therapy in the experimental arm, and fewer patients in this arm needed treatment delay and dose reduction compared with the standard arm. Likewise, a clear trend to better global health status/QOL and a significant improvement of physical functioning and constipation were reported in the experimental arm. Although QOL data yield complementary information, they add value to our study, being associated with real clinical benefit and considering that QOL reporting was not available in most recently published phase 3 trials in mCRC.32
In recent years, an emerging new concept explored in preclinical models suggests that the mechanism behind improvement in survival with antiangiogenic therapy may be related—in addition to tumor size reduction—to off-tumor targets.33 Antiangiogenic drugs may improve chemotoxic tolerance by modulating the function of various tissues and organs through systemic alteration of the vasculature, thus preventing cancer-associated systemic syndromes.33 In this regard, our safety data are consistent with preclinical evidence showing a significant reduction of chemotoxic effects and a superior survival effect with the sequential delivery of antiangiogenic drugs and chemotherapy compared with concomitant administration.34
On the other hand, several studies have suggested that antiangiogenic drugs may act as chemosensitizing agents by blunting the protumorigenic and prometastatic effects of the host response to conventional chemotherapy.35 Importantly, a recent preclinical study36 showed that scheduling of bevacizumab administration 3 days before chemotherapy improved antitumor efficacy and reduced metastatic spread compared with concomitant administration. These additional mechanisms could explain how antiangiogenic agents can improve efficacy of chemotherapy beyond vessel normalization and suggest that the potential synergistic effect of antiangiogenesis in combination treatment may not be determined only by the improvement of drug delivery. Several preclinical and clinical studies with radiolabeled drugs37 have questioned the postulated mechanism of improved drug delivery as a consequence of anti-VEGF treatment. Moreover, tumor uptake of radiolabeled drugs may not be a good predictor of clinical benefit.38
The importance of vascular normalization and of bevacizumab scheduling to optimize the efficacy of treatment has been reported with several combination therapies.39 Compelling recent findings also show that vascular normalization might favor an immune-supportive tumor microenvironment, suggesting the combination of bevacizumab with immunotherapy as an attractive anticancer therapeutic approach.40 Interestingly, mathematical models suggest that antiangiogenic treatment may improve immunotherapy when the 2 treatments are administered sequentially.41 Overall, these findings suggest that host response and off-tumor targets may be more relevant in the sequential schedule and could explain, at least in part, the discordance between ORR and survival outcome observed in our trial.
Our study has some limitations. Considering that the accuracy of conventional evaluation of tumor response by RECIST criteria to bevacizumab combination treatment has been questioned,42,43 we acknowledge that our choice of ORR as primary end point may have been inadequate. Indeed, several lines of evidence suggest that alternative morphological criteria such as the MD Anderson criteria are better correlated with long-term outcome.43 We are also aware that balancing out unmeasurable differences in patient outcome through randomization is not always achieved with confidence in trials with a relatively small sample size, as in our study. In addition, we cannot definitively rule out that a different interval between bevacizumab and chemotherapy could improve the efficacy of combination treatment.44
The results of this randomized clinical trial failed to show an improvement of the primary end point ORR from the sequential administration of bevacizumab in combination with standard oxaliplatin-based regimens in unselected patients with RAS mutations and mCRC. However, although hypothesis generating, the OS advantage, fewer adverse effects, and better health-related QOL observed in the sequential scheduling of bevacizumab administration compared with concomitant administration warrant consideration for additional clinical studies. Indeed, sequential bevacizumab administration plus chemotherapy might be relevant to optimize therapeutic efficacy and to explore antiangiogenic combination treatments with an innovative perspective.
Accepted for Publication: May 22, 2021.
Published: July 26, 2021. doi:10.1001/jamanetworkopen.2021.18475
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Avallone A et al. JAMA Network Open.
Corresponding Author: Antonio Avallone, MD, Experimental Clinical Abdomen Oncology Unit, Istituto Nazionale Tumori–Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione G. Pascale, via M Semmola 80131, Napoli, Italy (firstname.lastname@example.org).
Author Contributions: Drs Avallone and Piccirillo had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Avallone, Piccirillo, Aloj, Perrone, Budillon.
Acquisition, analysis, or interpretation of data: Avallone, Piccirillo, Nasti, Rosati, Carlomagno, Di Gennaro, Romano, Tatangelo, Granata, Cassata, Silvestro, De Stefano, Aloj, Vicario, Nappi, Leone, Bilancia, Arenare, Petrillo, Lastoria, Gallo, Botti, Delrio, Izzo, Perrone, Budillon.
Drafting of the manuscript: Avallone, Piccirillo, Aloj, Perrone, Budillon.
Critical revision of the manuscript for important intellectual content: Avallone, Piccirillo, Nasti, Rosati, Carlomagno, Di Gennaro, Romano, Tatangelo, Granata, Cassata, Silvestro, De Stefano, Aloj, Vicario, Nappi, Leone, Bilancia, Arenare, Petrillo, Lastoria, Gallo, Botti, Delrio, Izzo, Perrone, Budillon.
Statistical analysis: Piccirillo, Arenare, Gallo, Perrone.
Obtained funding: Avallone, Lastoria, Budillon.
Administrative, technical, or material support: Avallone, Piccirillo, Di Gennaro, Tatangelo, Granata, Aloj, Vicario, Leone, Petrillo, Lastoria, Botti, Delrio, Izzo.
Supervision: Avallone, Piccirillo, Perrone, Budillon.
Other (recruitment and management of study participants; participation in investigation meetings): Carlomagno, Rosati, Bilancia.
Other (patient enrollment and supervision of study interventions): Nasti, Cassata, Silvestro, Nappi, Romano, De Stefano.
Conflict of Interest Disclosures: Dr Avallone reported receiving personal fees from Amgen Inc, Sanofi SA, and Servier Laboratories; research grants from Amgen Inc; and consulting or advisory fees from Amgen Inc outside the submitted work. Dr Piccirillo reported receiving research grants from AstraZeneca; personal fees from AstraZeneca and Daichi Sankyo Company, Limited, for educational talks; and research grants from Bayer and Roche outside the submitted work. Dr Gallo reported receiving personal fees for educational talks from AstraZeneca outside the submitted work. Dr Perrone reported receiving nonfinancial support from Bayer and personal fees from Laboratoire Pierre Fabre; Clovis Oncology, Inc; Ipsen; Merck & Co, Inc; and Tesaro/GlaxoSmithKline plc outside the submitted work. Dr Budillon reported receiving research grants from Amgen Inc and Roche outside the submitted work. No other disclosures were reported.
Funding/Support: This clinical trial was supported by grant RF-2009-1539464 from the Italian Ministry of Health.
Role of the Funder/Sponsor: The Italian Ministry of Health verified that the work fulfills the research plan submitted for grant application but otherwise had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank the patients and their families, the nurses, and the investigators who participated in this study. Manuela Florio, Clinical Trials Unit, Istituto Nazionale Tumori–Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, and Marco Borrelli, BE, Experimenta Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori–IRCCS, Fondazione G. Pascale, contributed as data managers. Antonia Del Giudice, MSc, Giuliana Canzanella, Manuela Florio, Giovanni De Matteis, Fiorella Romano, MEc, Alfonso Savio, MSc, Lucia Sparavigna, MSc, Marilena Martino, MLA, and Maria Teresa Ribecco, MSc, Clinical Trials Unit, Istituto Nazionale Tumori–IRCCS, Fondazione G. Pascale, contributed as study coordinators. They did not receive compensation for this work.